Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,198B 70.72B 63.43B 57.97B 52.92B 99.7B 6,648B 103B 699B 279B 3,547B 265B 260B P/E 2026 *
22x
P/E 2027 * 19.4x
Enterprise Value 10,280B 64.92B 58.23B 53.22B 48.58B 91.53B 6,103B 94.41B 641B 256B 3,256B 244B 238B EV / Sales 2026 *
7.38x
EV / Sales 2027 * 6.59x
Free-Float
38.12%
Yield 2026 *
1.98%
Yield 2027 * 2.24%
1 day-5.34%
1 week-0.23%
Current month-0.23%
1 month+11.21%
3 months+0.62%
6 months-17.45%
Current year-17.43%
1 week 6,700
Extreme 6700
7,381
1 month 5,979
Extreme 5979
7,381
Current year 5,974
Extreme 5974
10,700
1 year 5,974
Extreme 5974
10,700
3 years 4,572
Extreme 4572
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.333333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
-5.34%-0.23%-2.09%+45.15% 70.72B
-0.79%-4.48%+44.44%+127.49% 1,206B
+1.43%+1.11%+47.73%+82.08% 665B
+1.07%-1.21%+32.99%+106.31% 515B
-0.36%-3.25%+47.17%+64.58% 381B
-0.14%-1.87%+71.05%+40.63% 362B
-0.78%-0.52%+30.57%+57.98% 307B
-0.80%-0.21%+8.54%+35.56% 289B
+0.03%-1.20%+45.89%+68.76% 249B
-0.41%-2.22%+35.24%+105.68% 207B
Average -0.61%-1.41%+36.16%+73.42% 425.05B
Weighted average by Cap. -0.13%-1.93%+41.50%+87.66%

Financials

2026 *2027 *
Net sales 1,393B 8.8B 7.89B 7.21B 6.58B 12.4B 827B 12.79B 86.9B 34.65B 441B 33.01B 32.31B 1,522B 9.61B 8.62B 7.88B 7.19B 13.55B 904B 13.98B 94.97B 37.87B 482B 36.08B 35.3B
Net income 510B 3.22B 2.89B 2.64B 2.41B 4.54B 303B 4.68B 31.8B 12.68B 161B 12.08B 11.82B 577B 3.64B 3.27B 2.99B 2.73B 5.14B 342B 5.3B 35.99B 14.35B 183B 13.67B 13.38B
Net Debt -918B -5.8B -5.2B -4.75B -4.34B -8.17B -545B -8.43B -57.26B -22.83B -291B -21.75B -21.29B -1,165B -7.36B -6.6B -6.03B -5.5B -10.37B -691B -10.7B -72.68B -28.98B -369B -27.61B -27.02B
Projected Income Statement - Annual - Chugai Pharmaceutical Co., Ltd.
Logo Chugai Pharmaceutical Co., Ltd.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Employees
5,104
Date Price Change Volume
06/11/26 JPY 6,806.00 -5.34% 5,246,700
05/11/26 JPY 7,190.00 +4.28% 4,737,600
04/11/26 JPY 6,895.00 +0.76% 3,837,300
02/11/26 JPY 6,843.00 +0.31% 3,195,800
30/10/26 JPY 6,822.00 +2.54% 3,076,400
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Chugai Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,806.00JPY
Average target price
8,446.67JPY
Spread / Average Target
+24.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Chugai Pharmaceutical Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 4519 Stock